EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY-NC-ND 4.0

Scoping review of biosimilar disease-modifying antirheumatic drugs in pregnancy: evidence gaps and proposed outcome reporting framework

Vienna Cheng iD, Neda Amiri iD, Vicki Cheng iD, Ursula Ellis iD, Jacquelyn J Cragg iD, Laurie Proulx iD, Dwayne R Tucker iD, Mary A De Vera iD

Rheumatology International · 2025

DOI: 10.1007/s00296-025-05968-3 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Rheumatology International, 2025. Verfasst von Vienna Cheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V6T 1Z3, Canada. Hauptthemen laut MEDLINE: Antirheumatic Agents, Biosimilar Pharmaceuticals, Pregnancy Complications. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Arthritis Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biologic disease-modifying antirheumatic drugs (DMARDs) have revolutionized the management of autoimmune diseases. Biosimilar DMARDs have emerged as highly similar, cost-efficient alternatives; however, the scope of their perinatal evidence remains unexplored. We conducted a scoping review to synthesize evidence on the impact of biosimilar DMARDs on pregnancy outcomes. We searched Embase, MEDLINE and CENTRAL databases in November 2023 and June 2025. Inclusion criteria were studies examining biosimilar DMARD exposure for autoimmune diseases in mothers during pregnancy, fathers prior to conception and/or fetuses/neonates in-utero. Data were extracted on sample size, study design, drug exposure (timing, duration), and pregnancy outcomes. Patterns in methodologic reporting across studies were also analyzed. Overall, 6 studies (5 descriptive, 1 cohort study) were eligible for inclusion. Biosimilars examined were tumor necrosis factor inhibitors (infliximab, n = 4; etanercept, n = 2; adalimumab, n = 1) and B-cell inhibitors (rituximab, n = 1) among 63 mothers with inflammatory bowel disease, rheumatoid arthritis, or ankylosing spondylitis. Twenty-four fetal/neonatal (i.e., congenital anomaly), fetal/neonatal-maternal (i.e., Caesarean-section, spontaneous abortion), and maternal (i.e., disease flare) outcomes were reported. For methodologic reporting, we observed inconsistencies in exposure and outcome measures. To enhance comparability and standardization, we encourage the use of our Reproductive Health Outcomes Reporting Framework. Our scoping review is the first synthesis of perinatal evidence to date on biosimilar DMARDs. Critical gaps include an overall limited number of studies and a lack of analytical research that evaluate associations between exposures and outcomes. These findings highlight key evidence gaps in understanding the perinatal impacts of these emerging drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsBiosimilar PharmaceuticalsPregnancy ComplicationsHumansPregnancyFemalePregnancy OutcomeEvidence Gaps

Stichwörter der Autor:innen

Antirheumatic agentsAutoimmune diseaseBiologicalsBiosimilarPregnancy outcome

Substanzen

Antirheumatic AgentsBiosimilar Pharmaceuticals

Autor:innen und Institutionen

  • Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V6T 1Z3, Canada.
  • Collaboration for Outcomes Research and Evaluation, Vancouver, BC, Canada.
  • Arthritis Research Canada, Vancouver, BC, Canada.
  • Division of Rheumatology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Mary Pack Arthritis Centre, Vancouver, BC, Canada.
  • Woodward Library, University of British Columbia, Vancouver, BC, Canada.

ORCID-Profile: Vienna Cheng, Neda Amiri, Vicki Cheng, Ursula Ellis, Jacquelyn J Cragg, Laurie Proulx, Dwayne R Tucker, Mary A De Vera

Förderung

  • Arthritis Society

Zitieren

APA

Cheng, V., Amiri, N., Cheng, V., Ellis, U., Cragg, J. J., Proulx, L., Tucker, D. R., & De Vera, M. A. (2025). Scoping review of biosimilar disease-modifying antirheumatic drugs in pregnancy: evidence gaps and proposed outcome reporting framework. Rheumatology International. https://doi.org/10.1007/s00296-025-05968-3

Vancouver

Cheng V, Amiri N, Cheng V, Ellis U, Cragg JJ, Proulx L, et al. Scoping review of biosimilar disease-modifying antirheumatic drugs in pregnancy: evidence gaps and proposed outcome reporting framework. Rheumatology International. 2025. doi:10.1007/s00296-025-05968-3

BibTeX
@article{Cheng2025,
  author = {Cheng, Vienna and Amiri, Neda and Cheng, Vicki and Ellis, Ursula and Cragg, Jacquelyn J and Proulx, Laurie and Tucker, Dwayne R and De Vera, Mary A},
  title = {Scoping review of biosimilar disease-modifying antirheumatic drugs in pregnancy: evidence gaps and proposed outcome reporting framework},
  journal = {Rheumatology International},
  year = {2025},
  doi = {10.1007/s00296-025-05968-3}
}
Kostenlos starten →